Clinical Trial: A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138196) titled 'A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease' on Aug. 11.

Brief Summary: Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).

Study Start Date: Nov. 17, 2025

Study Type: INTERVENTIONAL

Condition: Chronic Graft-Versus-Host Disease

Intervention: DRUG: Adrixetinib

Administered orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Qurient Co., Ltd.

Published by HT Digital Content Services with p...